Based on good tumor growth inhibition with compound 9 in WiDr tumor model, and also based on its superior metabolic disruption properties compared to 3, compound 9 was further advanced for in vivo studies in the MCT4 expressing MDA-MB-231 tumor xenograft model. The gene discussed is SLC16A3; the disease is neoplasm.